AstraZeneca's Brilinta gets into the FDA's fast lane for new use

AstraZeneca's ($AZN) clot-fighter Brilinta got a lift from the FDA Wednesday, as the agency said it would fast-track review of the drug for broader use. The drugmaker could get an OK in the third quarter, for use in heart attack patients up to three years after the event. Release

Suggested Articles

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

Novo Nordisk just won an FDA approval that could help it stand out in the crowded—and competitive—basal insulin category.

Pfizer is training pharmacists in the U.K. to handle over-the-counter Viagra.